Literature DB >> 17492410

[Radiotherapy for prostate cancer].

Christian Stanek1.   

Abstract

Depending on tumor-stage and risk-factors, prostate cancer can be treated by Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, Androgen Ablation or a combination of at least two of them. In clinically localized low-risk cases, the results of radiotherapy and surgery are very similar. Patients with intermediate-risk or high-risk prostate cancer, often not suited for radical prostatectomy, seem to benefit from higher radiation doses and additional Androgen ablation, although questions remain regarding the treatment volume of radiotherapy and the optimal timing and duration of androgen deprivation. Standardised target volume definitions and dose prescriptions for different risk groups and improved patient selection for radiotherapy are required.

Entities:  

Mesh:

Year:  2007        PMID: 17492410     DOI: 10.1007/s10354-007-0404-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  36 in total

1.  Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.

Authors:  Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

2.  Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins.

Authors:  Bin S Teh; Michael D Bastasch; Wei-Yuan Mai; Michael W Kattan; E Brian Butler; Dov Kadmon
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

3.  Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy).

Authors:  Michael Pinkawa; Jaroslav Siluschek; Bernd Gagel; Marc D Piroth; Cengiz Demirel; Branka Asadpour; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2007-01       Impact factor: 3.621

4.  Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?

Authors:  Richard Choo; George Hruby; Julie Hong; Eugene Hong; Gerrit DeBoer; Cyril Danjoux; Gerard Morton; Laurence Klotz; Edward Bhak; Aileen Flavin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-01       Impact factor: 7.038

5.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Authors:  Mack Roach; Michelle DeSilvio; Richard Valicenti; David Grignon; Sucha O Asbell; Colleen Lawton; Charles R Thomas; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

6.  Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer.

Authors:  Charles Catton; Mary Gospodarowicz; Jimmy Mui; Tony Panzarella; Michael Milosevic; Michael McLean; Pamela Catton; Padraig Warde
Journal:  Can J Urol       Date:  2002-02       Impact factor: 1.344

7.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

8.  Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

Authors:  Brian Lee; Katsuto Shinohara; Vivian Weinberg; Alexander R Gottschalk; Jean Pouliot; Mack Roach; I-Chow Hsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

9.  Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.

Authors:  J E Johansson; L Holmberg; S Johansson; R Bergström; H O Adami
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

10.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.